Source: Venture Capital Journal

Dyne: VC-backed Dyne Therapeutics goes public

Dyne Therapeutics Inc, a muscle disease company, has raised about $233 million for its IPO after pricing its over 12.2 million shares at $19 per share.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Joshua Brumm's photo - President & CEO of Dyne Therapeutics

President & CEO

Joshua Brumm

CEO Approval Rating

90/100

Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Read more